Chemotherapy for Ovarian Cancer
Open Access
- 9 May 1996
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 334 (19) , 1268-1270
- https://doi.org/10.1056/nejm199605093341912
Abstract
As reported by McGuire et al. (Jan. 4 issue),1 the results of the Gynecologic Oncology Group's phase 3 trial comparing paclitaxel plus cisplatin with cyclophosphamide plus cisplatin in women with ovarian cancer are exciting and encouraging. However, the data from this trial need to be interpreted with caution, for a number of reasons.Keywords
This publication has 8 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1995
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancerThe Lancet, 1992
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991